We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBiofrontera Inc

Biofrontera Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.9262 USD -0.01 ( 1.21%)
Last update at 2026-11-12T15:37:00Z
VOLUME
12065
Market Cap
12.70M

Momentum Score

…

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.91
Low
0.94
High
52 Week Price Range
0.54
Low
1.19
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Biofrontera Inc is a specialty dermatology company that develops and commercializes photodynamic therapy products, notably Ameluz, for treatment of actinic keratosis and related skin conditions in the U.S. and Europe. Long-term growth may be supported by wider clinical adoption, geographic expansion, and pipeline commercialization. The company provides exposure to a focused approved dermatology franchise with upside if adoption and reimbursement improve.

Key risks include reliance on one core product, small commercial scale and historical losses that may require further financing, regulatory and reimbursement uncertainty, and competition from alternative therapies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.94
Dividend Yield
-
Revenue TTM
41.70M
Revenue Per Share
4.10
Gross Profit TTM
30.74M
Debt / Equity
0.59
ROE
-141.30%
Net Debt
-0.23M
ROCE
-68.08%
Diluted EPS TTM
-1.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.51M -17.74M -20.12M -0.61M -37.66M
Net income -10.54M -17.76M -20.13M -0.64M -37.71M
Selling general administrative 38.37M 33.84M 37.70M 35.87M 37.21M
Selling and marketing expenses - - 1.43M 0.73M 0.70M
Gross profit 31.59M 18.70M 16.63M 13.49M 11.36M
Reconciled depreciation 0.87M 1.15M 1.55M 1.17M 0.54M
Ebit -11.35M -15.59M -19.52M -22.38M -25.85M
Ebitda -10.48M -14.44M -18.45M -21.18M -25.16M
Depreciation and amortization 0.87M 1.15M 1.06M 1.21M 0.69M
Operating income -11.35M -17.21M -22.68M -22.38M -25.85M
Other operating expenses 53.05M 54.53M 56.75M 51.05M 49.95M
Interest expense 0.45M 2.11M 0.60M 0.20M 0.34M
Tax provision 0.03M 0.02M 0.02M 0.03M 0.06M
Interest income - 0.07M 0.17M 0.17M 0.02M
Net interest income -0.45M -2.08M -0.29M -0.20M -0.34M
Income tax expense 0.03M 0.02M 0.01M 0.03M 0.06M
Total revenue 41.70M 37.30M 34.07M 28.67M 24.10M
Total operating expenses 42.94M 35.92M 39.30M 35.87M 37.21M
Cost of revenue 10.11M 18.61M 17.44M 15.19M 12.74M
Total other income expense net 0.84M -0.53M 2.56M 21.77M -11.81M
Net income from continuing ops -10.54M -17.76M -26.44M -0.64M -37.71M
Net income applicable to common shares - - - -0.64M -37.71M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 28.56M 22.10M 27.93M 50.88M 53.22M
Intangible assets 2.65M 0.04M 2.63M 3.03M 3.45M
Other current assets 2.97M 2.83M 5.58M 0.81M 4.99M
Total liab 18.08M 17.67M 23.14M 27.00M 41.88M
Total stockholder equity 10.48M 4.43M 4.79M 23.88M 11.34M
Other current liab 4.90M 9.62M 4.49M 12.18M 3.24M
Common stock 0.01M 0.01M 0.00M 0.03M 0.02M
Capital stock 0.01M 0.01M 0.00M 0.03M 0.02M
Retained earnings -127.94M -117.41M -99.65M -79.52M -78.88M
Other liab - - - 5.26M 28.05M
Other assets - - 0.00M 3.13M 3.08M
Cash 6.39M 5.91M 1.34M 17.21M 24.55M
Total current liabilities 11.89M 12.02M 18.09M 20.89M 13.84M
Current deferred revenue - - - 6.94M 3.24M
Net debt -0.23M -0.98M 4.06M -15.86M -24.55M
Short term debt 0.33M 0.55M 4.59M 0.50M 6.69M
Short long term debt - - 3.90M - -
Short long term debt total 6.16M 4.92M 5.40M 1.35M -
Other stockholder equity 138.41M 121.83M 104.44M 103.37M 90.20M
Property plant equipment - - - 1.58M 0.27M
Total current assets 18.08M 20.70M 23.07M 43.14M 46.42M
Net tangible assets - - - 20.85M 7.89M
Short term investments 0.01M 0.01M 0.08M 10.55M -
Net receivables 7.29M 5.32M 5.16M 7.41M 12.43M
Long term debt 4.59M 4.10M - - -
Inventory 1.43M 6.65M 10.91M 7.17M 4.46M
Accounts payable 6.67M 1.86M 9.01M 1.28M 0.66M
Non currrent assets other 3.89M 0.38M 0.28M 3.13M 3.08M
Non current assets total 10.48M 1.40M 4.86M 7.74M 6.80M
Capital lease obligations 1.57M 0.82M 1.50M 1.35M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M -0.00M -1.54M -5.16M -0.01M
Change to liabilities - - - 0.91M -0.77M
Total cashflows from investing activities 3.00M -0.00M 0.62M -5.16M -0.01M
Net borrowings 0.00M -0.27M 3.90M - -
Total cash from financing activities 10.85M 14.84M 8.41M 14.02M 43.19M
Change to operating activities - - - 4.76M -2.71M
Net income -10.54M -17.76M -20.13M -0.64M -37.71M
Change in cash 0.49M 4.56M -15.87M -7.33M 16.46M
Begin period cash flow 6.11M 1.54M 17.41M 24.74M 8.28M
End period cash flow 6.59M 6.11M 1.54M 17.41M 24.74M
Total cash from operating activities -13.36M -10.27M -24.89M -16.20M -26.71M
Issuance of capital stock 10.85M 7.66M 4.51M 9.39M 29.94M
Depreciation 0.14M 1.15M 1.06M 1.17M 0.54M
Other cashflows from investing activities 3.00M -0.05M - - -
Change to inventory 1.45M 4.23M -3.75M -2.81M 2.59M
Change to account receivables -1.91M -0.31M 4.93M -0.07M -0.61M
Other cashflows from financing activities -10.85M 15.10M 3.90M 4.63M 13.25M
Change to netincome - - - -19.52M 11.96M
Capital expenditures 0.00M 0.06M 0.01M 0.04M 0.01M
Change in working capital -3.48M 6.21M -4.39M 2.79M -1.50M
Stock based compensation 0.95M 1.02M 1.04M 1.85M 0.13M
Other non cash items -0.43M -0.89M -2.48M -21.37M -1.04M
Free cash flow -13.36M -10.33M -24.90M -16.24M -26.73M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BFRI
Biofrontera Inc		 -0.01
1.21%		 0.93 - 13.64 0.30 1.21 0.30 -0.79
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Biofrontera Inc

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

660 Main Street, Woburn, MA, United States, 01801

781 245 1325

https://www.biofrontera-us.com

84

Name Title Year Born
Dr. Hermann Lubbert Ph.D. Exec. Chairman & Pres 1956
Ms. Erica L. Monaco CPA CEO, COO, Treasurer & Sec. 1985
Mr. Eugene Fredrick Leffler III Chief Financial Officer 1984
Ms. Erica F. Gates CPA, M.B.A. Sr. Director of Fin. & Principal Accounting Officer NA
Ms. Alycia Torres VP of Admin. NA
Mr. Daniel Hakansson J.D. Gen. Counsel & Head of Compliance NA
Mr. Mark Baldyga Head of Sales & Marketing NA
Mr. Jeff Holm Head of Professional Relations & Commercial Devel. NA
Dr. Hermann Luebbert Ph.D. CEO, President & Executive Chairman 1956
Mr. Eugene Frederick Leffler III Chief Financial Officer 1985

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…